{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:46:26Z","timestamp":1792010786692,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.aohep.2026.102254","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:46:33Z","timestamp":1781279193000},"page":"102254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting"],"prefix":"10.1016","volume":"32","author":[{"given":"Annegret","family":"Franke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9233-4064","authenticated-orcid":false,"given":"Johannes","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aohep.2026.102254_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/a-2558-5204","volume":"63","year":"2025","journal-title":"Z Gastroenterol"},{"issue":"10266","key":"10.1016\/j.aohep.2026.102254_bib0003","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.aohep.2026.102254_bib0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102254_bib0005","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.jhepr.2024.101168","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep: Innov Hepatol"},{"issue":"1S Suppl 1","key":"10.1016\/j.aohep.2026.102254_bib0006","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/MEG.0000000000002011","article-title":"Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium","volume":"33","author":"Pariente","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Cortez-Pinto","year":"2021","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"10.1016\/j.aohep.2026.102254_bib0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/jcm10051061","article-title":"Real-world clinical management of patients with primary biliary cholangitis-a retrospective multicenter study from Germany","volume":"10","author":"Wilde","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.aohep.2026.102254_bib0009","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102254_bib0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing therapy in primary biliary cholangitis: alkaline phosphatase at six months identifies one-year non-responders and predicts survival","volume":"43","author":"Murillo Perez","year":"2023","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"issue":"11","key":"10.1016\/j.aohep.2026.102254_bib0011","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1055\/a-2382-7720","article-title":"Sub-optimale behandlung von Patienten mit Prim\u00e4r Bili\u00e4rer Cholangitis (PBC) im klinischen Alltag der deutschen PBC Kohorte (Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort)","volume":"62","author":"Wiegand","year":"2024","journal-title":"Z Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0012","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0013","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102254_bib0014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","article-title":"Factors associated with progression and outcomes of early stage primary biliary cholangitis","volume":"18","author":"Gatselis","year":"2020","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"10","key":"10.1016\/j.aohep.2026.102254_bib0015","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102254_bib0016","first-page":"626","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The lancet","volume":"3","author":"Carbone","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"8","key":"10.1016\/j.aohep.2026.102254_bib0017","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1007\/s10620-021-07219-4","article-title":"Dynamic risk prediction of response to ursodeoxycholic acid among patients with primary biliary cholangitis in the USA","volume":"67","author":"Li","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0018","first-page":"240","article-title":"How the concept of biochemical response influenced the management of primary biliary cholangitis over time","volume":"74","author":"Lammers","year":"2016","journal-title":"Neth J Med"},{"issue":"9","key":"10.1016\/j.aohep.2026.102254_bib0019","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of Seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.aohep.2026.102254_bib0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.aohep.2026.102254_bib0021","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102254_bib0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"10","key":"10.1016\/j.aohep.2026.102254_bib0025","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clinic Gastroenter Hepatol: Offic Clinic Pract J Am Gastroenterol Associat"},{"issue":"12","key":"10.1016\/j.aohep.2026.102254_bib29","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clinic Gastroenterol Hepatol: Offici Clinic Practice. J Am Gastroenterol Associat"},{"issue":"6","key":"10.1016\/j.aohep.2026.102254_bib0026","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102254_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:03:51Z","timestamp":1792008231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1665268126000748"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102254","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102254"}}